Triptan use and risk of cardiovascular events: A nested-case-control study from the French health system database

European Journal of Clinical Pharmacology

Volumn 63, Issue 8, 2007, Pages 801-807

  Lugardon, S ^a   Roussel, H ^b   Sciortino, V ^b   Montastruc, J L ^a   Lapeyre Mestre, M ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

Author keywords

Cardiovascular events; Ischemic event; Overuse; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; ERGOT ALKALOID; NARATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HEADACHE; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SIDE EFFECT;

ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1D; RISK; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 34447332496     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0332-2     Document Type: Article

References (23)

1. Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lanteri-Minet M, Lucas C, Pradalier A, Chazot G, El Hasnaoui A (2002) Prevalence and clinical characteristics of migraine in France. Neurology 59(2):232-237
2. Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R (1992) A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM. Cephalalgia 12(4):229-237
3. Mitchell P, Wang JJ, Currie J, Cumming RG, Smith W (1998) Prevalence and vascular associations with migraine in older Australians. Aust N Z J Med 28(5):627-632
4. Jamieson DG (2002) The safety of triptans in the treatment of patients with migraine. Am J Med 112(2):135-140
5. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH (1993) Transmural myocardial infarction with sumatriptan. Lancet 341(8849):861-862
6. Laine K, Raasakka T, Mantynen J, Saukko P (1999) Fatal cardiac arrhythmia after oral sumatriptan. Headache 39(7):511-512
7. Mueller L, Gallagher RM, Ciervo CA (1996) Vasospasm-induced myocardial infarction with sumatriptan. Headache 36(5):329-331
8. Souyri C, Lacroix I, Pathak A, Montastruc JL (2005) Coronary adverse reactions to triptans: an analysis of the French pharmacovigilance database. Fund Clin Pharmacol 19:228, (Abstract)
9. Roussel H, Lo Re G, Honorat C, Alonso M, Sciortino V (2006) The use of triptan in ambulatory medicine in Midi-Pyrenees region: clinical and pharmacological contra-indications and drug abuse. Therapie 61(6):507-516
10. Gaits D, Hallas J, Sindrup SH, Gram LF (1996) Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 50(3):161-165
11. Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J (2004) Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 62(9):1540-1544
12. Gaist D (1999) Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. Cephalalgia 19(8):735-761
13. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ; International Headache Society (2005) The International Classification of Headache Disorders, 2nd edition (ICHD-II)-revision of criteria for 8.2 medication-overuse headache. Cephalalgia 25:460-465
14. Geraud G, Lanteri-Minet M, Lucas C, Valade D; French Society for the Study of Migraine Headache (SFEMC) (2004) French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 26:1305-1318
15. Lucas C, Auray JP, Gaudin AF, Dartigues JF, Duru G, Henry P, Lanteri-Minet M, Pradalier A, Chazot G, El Hasnaoui A (2004) Use and misuse of triptans in France: data from the GRIM2000 population survey. Cephalalgia 24(3):197-205
16. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S (2003) Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 43:44-48
17. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC (2003) Single use of sumatriptan: a patient interview study. Headache 43(2):109-116
18. Senard JM, Nachit-Ouinekh F, Becq JP, Chastan G, Fabre N, El Hasnaoui A (2004) Triptan use in general practice: a French pharmacoepidemiological study. Therapie 59(5):533-539
19. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM (2004) Severe vascular events in migraine patients. Headache 44(7):642-651
20. Hall GC, Brown MM, Mo J, MacRae KD (2004) Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62(4):563-568
21. Wammes-van der Heijden EA, Rahimtoola H, Leufkens HGM, Tijssen CC, Egberts ACG (2006) Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 67(7):1128-1134
22. Arveiler D, Wagner A, Ducimetière P, Montaye M, Ruidavets JB, Bingham A, Ferrieres J, Amouyel P, Haas B (2005) Trends in coronary heart disease in France during the second half of the 1990s. Eur J Cardiovasc Prev Rehabil 12(3):209-215
23. Moride Y, Abenhaim L (1994) Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 47(7):731-737